Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03515707
Recruitment Status : Recruiting
First Posted : May 3, 2018
Last Update Posted : May 16, 2019
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 15, 2022
Estimated Study Completion Date : July 30, 2022